Course and Prognosis of AA Amyloidosis in Patients with Psoriatic Arthritis: Report of Three Cases from a Single Center Cohort and Review of the Literature
- PMID: 36128216
- PMCID: PMC9450196
- DOI: 10.31138/mjr.33.2.185
Course and Prognosis of AA Amyloidosis in Patients with Psoriatic Arthritis: Report of Three Cases from a Single Center Cohort and Review of the Literature
Abstract
Objective: Herein, we aimed to evaluate the frequency and clinical features of AA amyloidosis in patients with PsA followed up in our tertiary referral clinic.
Methods: We retrospectively evaluated PsA patients classified according to CASPAR classification criteria followed-up in our tertiary referral clinic for AA amyloidosis. The literature search was also done by three independent researchers using the keywords "psoriatic arthritis AND amyloidosis", "spondyloarthritis AND amyloidosis", "AA amyloidosis", "secondary amyloidosis".
Results and conclusions: A total of 253 patients were included into the analysis. Two thirds of (n=162; 64%) the patients were women, and the mean age of the patients was 50.6 ± 13.4 (range, 20-90). We identified three patients with AA amyloidosis in 253 patients with PsA (1.2 %). The frequency of PsA-related amyloidosis in our AA amyloidosis cohort (n=165) was 1.8 %. Literature search revealed only a retrospective cohort study and 17 case reports, and we analysed these 31 cases. Nearly half of the cases were male, mean age of the patients was 50.7±15.3 and mean age of amyloidosis diagnosis was 47.2±16.7 years. Most of these patients had both polyarticular and axial involvement (81.3%). AA amyloidosis is a rare in patients with PsA. It should be kept in mind that patients with PsA who have not received appropriate treatment for a long time and/or have refractory disease may develop AA amyloidosis.
Keywords: AA amyloidosis; MEFV variants; psoriatic arthritis.
© 2022 The Mediterranean Journal of Rheumatology (MJR).
Conflict of interest statement
Murat Bektaş: No disclosure
Nevzat Koca: No disclosure
Burak Ince: No disclosure
Yasemin Yalçınkaya: No disclosure
Bahar Artım Esen: No disclosure
M. Lale Öcal: No disclosure
Ahmet Gül: Consultancy Novartis Turkey
Murat Inanç: Consultancy Novartis Turkey
Similar articles
-
Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy.Rheumatology (Oxford). 2003 Feb;42(2):362-6. doi: 10.1093/rheumatology/keg101. Rheumatology (Oxford). 2003. PMID: 12595637
-
Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria.Clin Rheumatol. 2014;33(10):1489-93. doi: 10.1007/s10067-014-2651-x. Epub 2014 May 8. Clin Rheumatol. 2014. PMID: 24803232
-
Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria.Clin Exp Rheumatol. 2010 May-Jun;28(3):304-10. Epub 2010 Jun 23. Clin Exp Rheumatol. 2010. PMID: 20576225
-
Frequency of AA amyloidosis has decreased in Behçet's syndrome: a retrospective study with long-term follow-up and a systematic review.Rheumatology (Oxford). 2022 Dec 23;62(1):9-18. doi: 10.1093/rheumatology/keac223. Rheumatology (Oxford). 2022. PMID: 35657376
-
[Amyloidosis complicating psoriatic arthritis].Ann Dermatol Venereol. 2003 Nov;130(11):1039-42. Ann Dermatol Venereol. 2003. PMID: 14724539 Review. French.
References
-
- Eder L, Chandran V, Cook R, Gladman DD. The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study. J Rheumatol 2017;44:286–91. - PubMed
-
- Hazenberg BP. Amyloidosis: a clinical overview. Rheum Dis Clin North Am 2013;39:323–45. - PubMed
-
- Brunger AF, Nienhuis HLA, Bijzet J, Hazenberg BPC. Causes of AA amyloidosis: a systematic review. Amyloid 2020;27:1–12. - PubMed
-
- Rosa RG, Tonietto TF, da Silva DB, Gutierres FA, Ascoli AM, Madeira LC, et al. Effectiveness and Safety of an Extended ICU Visitation Model for Delirium Prevention: A Before and After Study. Crit Care Med 2017;45:1660–7. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous